ERBB2 and neoplasm: This difference in metabolic adaptation following Her2 downregulation between recurrent tumors that vary in latency alludes to an alternative source uniquely fueling the aggressive phenotype’s reactivation for recurrence not seen in the slow-recurrent tumor type.